Latest Administration News

Sims Limited is consolidating its Houston footprint by acquiring Tri Coastal Trading assets and selling its Mayo Shell property, aiming to boost EBITDA and cut costs significantly.

Paradigm Biopharmaceuticals has entered a binding agreement with AVet Health to co-develop and license a novel oral therapy for veterinary osteoarthritis in Australia and New Zealand, unlocking new market potential while advancing its human clinical trials.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.

Lindian Resources has placed orders for critical long-lead plant equipment and accelerated construction at its Kangankunde Rare Earths Project, targeting first ore feed by November 2026.

Bridge SaaS Limited has issued a correction to its Appendix 4C quarterly cash flow report, clarifying previously omitted financing facilities without affecting its cash position or operating results.

Imricor Medical Systems has taken a significant step toward US market entry by submitting its Advantage-MR EP Recorder/Stimulator system for FDA 510(k) clearance, aiming to enhance MRI-guided cardiac procedures.

Resouro Strategic Metals reports a $2.83 million loss for Q3 2025 while progressing its Tiros Titanium Dioxide and Rare Earth Elements Project, highlighted by an updated 1.9 billion tonne mineral resource estimate. The company also secured $3 million in a recent private placement, underpinning its exploration activities.

BlackRock Investment Management (Australia) Limited has announced confirmed cash distributions for four Australian iShares ETFs, detailing payment schedules and reinvestment options for investors.

Neuren Pharmaceuticals has received detailed feedback from the US FDA on its clinical development plans for NNZ-2591 targeting hypoxic ischemic encephalopathy and Pitt Hopkins syndrome, paving a clearer path forward despite some delays.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

Island Pharmaceuticals secures FDA confirmation on Galidesivir’s development under the Animal Rule, unlocking a streamlined two-stage approval process and significant commercial incentives.